Williams, W. B., Jones, K., Krambrink, A., Grove, D., Liu, P., Yates, N. L., … Tomaras, G. D. (2012). Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial. In Retrovirology (Vol. 9). Springer Science and Business Media LLC. https://doi.org/10.1186/1742-4690-9-s2-o55

Williams, W. B., K. Jones, A. Krambrink, D. Grove, P. Liu, N. L. Yates, M. A. Moody, et al. “Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial.” In Retrovirology, Vol. 9. Springer Science and Business Media LLC, 2012. https://doi.org/10.1186/1742-4690-9-s2-o55.

Williams WB, Jones K, Krambrink A, Grove D, Liu P, Yates NL, et al. Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial. In: Retrovirology. Springer Science and Business Media LLC; 2012.

Williams, W. B., et al. “Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial.” Retrovirology, vol. 9, no. S2, Springer Science and Business Media LLC, 2012. Crossref, doi:10.1186/1742-4690-9-s2-o55.

Williams WB, Jones K, Krambrink A, Grove D, Liu P, Yates NL, Moody MA, Ferrari G, Pollara J, Moodie Z, Morgan CA, Liao H, Montefiori DC, Ochsenbauer C, Kappes J, Hammer S, Mascola J, Koup R, Corey L, Nabel G, Gilbert P, Churchyard G, Keefer M, Graham BS, Haynes BF, Tomaras GD. Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial. Retrovirology. Springer Science and Business Media LLC; 2012.